Anti-inflammatory activity of lauric acid, thiocolchicoside and thiocolchicoside-lauric acid formulation.

Lauric acid anti-inflammatory agent dose dependant spectrophotometer thiocolchicoside

Journal

Bioinformation
ISSN: 0973-2063
Titre abrégé: Bioinformation
Pays: Singapore
ID NLM: 101258255

Informations de publication

Date de publication:
2023
Historique:
received: 01 11 2023
revised: 30 11 2023
accepted: 30 11 2023
medline: 4 12 2023
pubmed: 4 12 2023
entrez: 4 12 2023
Statut: epublish

Résumé

It is of interest to develop potent and safer anti-inflammatory drugs from plants, as medicinal plants and herbs attained great attention in the medical world due to their multifunctional activities. This article studied the anti-inflammatory effects of lauric acid (LA), thiocolchicoside (TC) and thiocolchicoside-lauric acid (TC-LA) formulation. The anti-inflammatory effects of these compounds were determined by following the methods of inhibition of protein denaturation and proteinase inhibition activity. This was assessed at different concentrations to determine the 50% inhibition concentration (IC50) of the compounds. The result indicated that the activity of LA, TC, TC-LA formulation, and reference drug increased with the increase in the concentration from 10-50 µg/ml, thus proving the activity of LA, TC, and TC-LA formulation against inflammation was in a dose-dependent manner. The percentage of inhibition of protein denaturation was 59.56%, 66.94%, 86.62%, and 60.34% for LA, TC, the combination of TC-LA and standard drug, and the IC50 values were found to be 44.78 µg/mL, 37.65 µg/mL, 27.15 µg/mL and 43.42 µg/mL, respectively. The percentage of proteinase inhibition activity of LA, TC, and a combination of TC-LA and the standard drug was 66.65%, 77.49%, 94.07%, and 69.83%, and IC50 of LA, TC, a combination of TC-LA and standard drug were35.5 µg/mL, 32.12 µg/mL, 24.35 µg/mL and 37.80 µg/mL, respectively. We found out that lauric acid, thiocolchicoside, and thiocolchicoside-lauric acid formulation exhibited significant anti-inflammatory activity.

Identifiants

pubmed: 38046516
doi: 10.6026/973206300191075
pii: 973206300191075
pmc: PMC10692977
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1075-1080

Informations de copyright

© 2023 Biomedical Informatics.

Références

J Pharm Res Int. 2021;33(58A):464-471
pubmed: 35024509
J Dermatol Sci. 2014 Mar;73(3):232-40
pubmed: 24284257
BMC Complement Altern Med. 2010 Jan 29;10:6
pubmed: 20109237
J Pharm Pharmacol. 1968 Mar;20(3):169-73
pubmed: 4385045
Ayu. 2018 Oct-Dec;39(4):239-242
pubmed: 31367147
J Pain. 2010 Sep;11(9):894-903
pubmed: 20418184
Arch Int Pharmacodyn Ther. 1964 May 1;149:1-7
pubmed: 14169882

Auteurs

Ameena Mustafa (A)

Department of Oral Pathology and Microbiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamilnadu, India.
Department of Oral Pathology and Microbiology, Azeezia College of Dental Sciences and Research, Meyyannoor, Kollam , Kerala, India.

Meignana Arumugham Indiran (M)

Department of Public Health Dentistry, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamilnadu, India.

Rajeshkumar Shanmugham (R)

Nanobiomedicine Lab, Department of Pharmacology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamilnadu, India.

Karthikeyan Ramalingam (K)

Department of Oral Pathology and Microbiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamilnadu, India.

Classifications MeSH